The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
出版年份 2023 全文链接
标题
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials
作者
关键词
-
出版物
European Heart Journal-Cardiovascular Pharmacotherapy
Volume 9, Issue 4, Pages 318-327
出版商
Oxford University Press (OUP)
发表日期
2023-03-28
DOI
10.1093/ehjcvp/pvad019
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
- (2022) Zhen Feng et al. Frontiers in Pharmacology
- 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
- (2021) Frank L J Visseren et al. EUROPEAN HEART JOURNAL
- Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study
- (2021) Adam Goldman et al. European Journal of Preventive Cardiology
- Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk
- (2020) Cécile Ingueneau et al. VASCULAR PHARMACOLOGY
- Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial
- (2019) Yundai Chen et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
- (2019) Robert S. Rosenson et al. DIABETOLOGIA
- Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks
- (2019) Naveed Sattar et al. CIRCULATION
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
- (2019) François Mach et al. EUROPEAN HEART JOURNAL
- Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
- (2019) Kausik K Ray et al. Lancet Diabetes & Endocrinology
- PCSK9 inhibitors and cardiovascular outcomes
- (2019) Daniel Steffens et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial
- (2018) Marja-Riitta Taskinen et al. ATHEROSCLEROSIS
- Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics
- (2018) Gerald F Watts et al. EUROPEAN HEART JOURNAL
- Rac1 Modulates Endothelial Function and Platelet Aggregation in Diabetes Mellitus
- (2018) Gabriele Giacomo Schiattarella et al. Journal of the American Heart Association
- Efficacy and Safety of Alirocumab in Japanese Patients with Diabetes Mellitus: Post-hoc Subanalysis of ODYSSEY Japan
- (2018) Tamio Teramoto et al. Journal of Atherosclerosis and Thrombosis
- PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes
- (2018) Matteo Monami et al. DIABETES OBESITY & METABOLISM
- Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
- (2017) Peter P. Toth et al. Journal of the American Heart Association
- Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
- (2017) Marc S Sabatine et al. Lancet Diabetes & Endocrinology
- Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome
- (2016) Dirk J. Blom et al. DIABETES OBESITY & METABOLISM
- Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo
- (2016) Peter P. Toth et al. Lipids in Health and Disease
- Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
- (2016) Naveed Sattar et al. Lancet Diabetes & Endocrinology
- Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia
- (2015) Eliano Pio Navarese et al. ANNALS OF INTERNAL MEDICINE
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
- (2015) C. Li et al. Journal of the American Heart Association
- Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
- (2014) Evan A. Stein et al. Annual Review of Medicine
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
- (2010) The Emerging Risk Factors Collaboration LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started